{"id":61150,"date":"2026-06-08T08:21:41","date_gmt":"2026-06-08T08:21:41","guid":{"rendered":"https:\/\/ibima.eu\/?page_id=61150"},"modified":"2026-06-08T08:21:44","modified_gmt":"2026-06-08T08:21:44","slug":"erdera-clinical-trial-call-2026-eu","status":"publish","type":"page","link":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/","title":{"rendered":"Erdera-Clinical Trial Call 2026.eu"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00bb1&#8243; admin_label=\u00bbsection\u00bb _builder_version=\u00bb4.25.1&#8243; custom_padding=\u00bb||0px|||\u00bb locked=\u00bboff\u00bb collapsed=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_5,3_5,1_5&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb21px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][et_pb_column type=\u00bb3_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2025\/11\/erdera-logo-1.png\u00bb title_text=\u00bberdera logo\u00bb align=\u00bbcenter\u00bb _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb32%\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb26px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb alt=\u00bberdera logo\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_image][\/et_pb_column][et_pb_column type=\u00bb1_5&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.5&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb59px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbClinical Trial Call 2026 \u2013 Pre-announcement\u00bb _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb title_text_align=\u00bbcenter\u00bb title_text_color=\u00bb#0C71C3&#8243; title_line_height=\u00bb1.3em\u00bb module_alignment=\u00bbcenter\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.6&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb1px|-78px|||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<div class=\"qMYqUG_convSearchResultHighlightRoot\">\n<div class=\"\" data-turn-id-container=\"request-WEB:d719cef9-8139-432c-ae88-89924fa3ab30-1\" data-is-intersecting=\"true\">\n<section class=\"text-token-text-primary w-full focus:outline-none has-data-writing-block:pointer-events-none [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto R6Vx5W_threadScrollVars scroll-mb-[calc(var(--scroll-root-safe-area-inset-bottom,0px)+var(--thread-response-height))] scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]\" dir=\"auto\" data-turn-id=\"request-WEB:d719cef9-8139-432c-ae88-89924fa3ab30-1\" data-turn-id-container=\"request-WEB:d719cef9-8139-432c-ae88-89924fa3ab30-1\" data-testid=\"conversation-turn-4\" data-scroll-anchor=\"false\" data-turn=\"assistant\">\n<div class=\"text-base my-auto mx-auto pb-3 [--thread-content-margin:var(--thread-content-margin-xs,calc(var(--spacing)*4))] @w-sm\/main:[--thread-content-margin:var(--thread-content-margin-sm,calc(var(--spacing)*6))] @w-lg\/main:[--thread-content-margin:var(--thread-content-margin-lg,calc(var(--spacing)*16))] px-(--thread-content-margin)\">\n<div class=\"[--thread-content-max-width:40rem] @w-lg\/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group\/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn\">\n<div class=\"flex max-w-full flex-col gap-4 grow\">\n<div data-message-author-role=\"assistant\" data-message-id=\"ea2b273d-1df0-47d4-9e38-2de60405e07c\" dir=\"auto\" data-message-model-slug=\"gpt-5-5\" class=\"min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal outline-none keyboard-focused:focus-ring [.text-message+&amp;]:mt-1\" data-turn-start-message=\"true\" tabindex=\"0\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden\">\n<div class=\"markdown prose dark:prose-invert wrap-break-word w-full light markdown-new-styling\">\n<p data-start=\"0\" data-end=\"508\" data-is-last-node=\"\" data-is-only-node=\"\" style=\"text-align: justify;\"><span>La Alianza Europea para la Investigaci\u00f3n en Enfermedades Raras (ERDERA) ha lanzado el preanuncio de la <\/span><strong><span>ERDERA Clinical Trial Call 2026<\/span><\/strong><span>, una convocatoria destinada a financiar ensayos cl\u00ednicos multinacionales en enfermedades raras. La iniciativa cuenta con un presupuesto de hasta <\/span><strong><span>30 millones de euros<\/span><\/strong><span> y forma parte de la asociaci\u00f3n europea ERDERA, cofinanciada por la Comisi\u00f3n Europea a trav\u00e9s de Horizon Europe.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<\/div>\n<\/div>\n<p>[\/et_pb_text][et_pb_heading title=\u00bbObjetivos de la convocatoria\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=\u00bbrow\u00bb _builder_version=\u00bb4.25.1&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb77.1%\u00bb custom_margin=\u00bb|-259px||161px||\u00bb custom_padding=\u00bb|0px||9px||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.16&#8243; custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb][et_pb_text admin_label=\u00bbText\u00bb _builder_version=\u00bb4.27.6&#8243; header_text_color=\u00bb#000000&#8243; background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb100%\u00bb custom_margin=\u00bb11px|-78px|-18px||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p data-start=\"2071\" data-end=\"2365\" style=\"text-align: justify;\"><span>La convocatoria financiar\u00e1 <\/span><strong><span>ensayos cl\u00ednicos intervencionistas multinacionales de Fase I, Fase I\/II o Fase II<\/span><\/strong><span>, promovidos por entidades acad\u00e9micas o cl\u00ednicas, que aborden enfermedades raras con una elevada necesidad m\u00e9dica no cubierta.<\/span><\/p>\n<p data-start=\"2071\" data-end=\"2365\" style=\"text-align: justify;\">La definici\u00f3n de enfermedad rara que se aplicar\u00e1 ser\u00e1 la establecida por la normativa europea: aquellas que afectan a menos de 5 personas por cada 10.000 habitantes. Adem\u00e1s, las propuestas deber\u00e1n centrarse en enfermedades graves, debilitantes o potencialmente mortales que presenten necesidades terap\u00e9uticas no cubiertas.<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul><\/ul>\n<\/li>\n<\/ul>\n<ul data-spread=\"false\" style=\"text-align: justify;\"><\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb10px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bb\u00c1reas prioritarias\u00bb _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p class=\"isSelectedEnd\"><span>Aunque cualquier enfermedad rara elegible podr\u00e1 presentarse, se dar\u00e1 especial consideraci\u00f3n estrat\u00e9gica a:<\/span><\/p>\n<ul data-spread=\"false\">\n<li><span>Enfermedades raras pedi\u00e1tricas.<\/span><\/li>\n<li><span>Enfermedades raras de progresi\u00f3n r\u00e1pida.<\/span><\/li>\n<li><span>Enfermedades raras sin tratamientos aprobados o con opciones terap\u00e9uticas insuficientes.<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb10px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbIntervenciones elegibles\u00bb _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p class=\"isSelectedEnd\"><span>La convocatoria apoyar\u00e1 estudios que eval\u00faen:<\/span><\/p>\n<ul data-spread=\"false\">\n<li><span>Nuevas mol\u00e9culas (New Chemical Entities, NCEs).<\/span><\/li>\n<li><span>F\u00e1rmacos reposicionados.<\/span><\/li>\n<li><span>Terapias avanzadas (ATMPs) con producci\u00f3n GMP validada.<\/span><\/li>\n<li><span>Productos biol\u00f3gicos innovadores (NBEs).<\/span><\/li>\n<li><span>Biol\u00f3gicos reposicionados.<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb14px|auto|-13px|159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbOut of Scope\u00bb _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li><span>Estudios precl\u00ednicos (in vitro, in silico o en animales).<\/span><\/li>\n<li><span>Estudios centrados exclusivamente en dispositivos m\u00e9dicos.<\/span><\/li>\n<li><span>Ensayos de Fase III o Fase IV.<\/span><\/li>\n<li><span>Estudios de farmacovigilancia.<\/span><\/li>\n<li><span>Enfermedades infecciosas raras.<\/span><\/li>\n<li><span>C\u00e1nceres raros (con excepciones espec\u00edficas para s\u00edndromes de predisposici\u00f3n tumoral y manifestaciones tumorales benignas asociadas a enfermedades gen\u00e9ticas raras).<\/span><\/li>\n<li><span>Evaluaciones econ\u00f3micas sin componente intervencionista.<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][et_pb_heading title=\u00bbCondiciones generales\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li style=\"text-align: justify;\">Pa\u00edses incluidos: Austria, B\u00e9lgica (Flandes), B\u00e9lgica (Comunidad franc\u00f3fona), B\u00e9lgica (Valonia), Bulgaria, Canad\u00e1 (CIHR-IG)<em data-start=\"131\" data-end=\"371\">, <\/em>Chipre, Rep\u00fablica Checa, Dinamarca, Estonia, Francia, Alemania, Hungr\u00eda, Irlanda, Israel, Italia, Letonia, Lituania, Luxemburgo, Noruega, Polonia, Portugal, Ruman\u00eda, Eslovaquia, Espa\u00f1a, Suecia, Pa\u00edses Bajos, Turqu\u00eda y Reino Unido (UKRI).<\/li>\n<li style=\"text-align: justify;\">M\u00ednimo: 3 socios elegibles de 3 pa\u00edses diferentes participantes.<\/li>\n<li style=\"text-align: justify;\">Hay que incluir al menos a una Asociaci\u00f3n de Pacientes como socia.<\/li>\n<li data-start=\"3799\" data-end=\"3826\" data-section-id=\"wl43lx\" style=\"text-align: justify;\">M\u00e1ximo 2 grupos del mismo pa\u00eds.<\/li>\n<li style=\"text-align: justify;\">Duraci\u00f3n de los proyectos: Depende del proyecto, hasta los 7 a\u00f1os.\u00a0\n<ul><\/ul>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb14px|auto|-13px|159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbFINANCIACI\u00d3N\u00bb _builder_version=\u00bb4.27.5&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<p data-start=\"53\" data-end=\"282\">Esta convocatoria dispone de un mecanismo de financiaci\u00f3n centralizado y se estima que cada ensayo cl\u00ednico podr\u00e1 recibir entre <strong data-start=\"180\" data-end=\"207\">1 y 5 millones de euros<\/strong>, en funci\u00f3n de sus caracter\u00edsticas, alcance y necesidades presupuestarias.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb33px|auto|-13px|159px|false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbOut of Scope\u00bb _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb sticky_enabled=\u00bb0&#8243;][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb min_height=\u00bb88px\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li><span>Estudios precl\u00ednicos (in vitro, in silico o en animales).<\/span><\/li>\n<li><span>Estudios centrados exclusivamente en dispositivos m\u00e9dicos.<\/span><\/li>\n<li><span>Ensayos de Fase III o Fase IV.<\/span><\/li>\n<li><span>Estudios de farmacovigilancia.<\/span><\/li>\n<li><span>Enfermedades infecciosas raras.<\/span><\/li>\n<li><span>C\u00e1nceres raros (con excepciones espec\u00edficas para s\u00edndromes de predisposici\u00f3n tumoral y manifestaciones tumorales benignas asociadas a enfermedades gen\u00e9ticas raras).<\/span><\/li>\n<li><span>Evaluaciones econ\u00f3micas sin componente intervencionista.<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb min_height=\u00bb264px\u00bb custom_margin=\u00bb20px|auto||159px|false|false\u00bb custom_padding=\u00bb||0px|||\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbfechas clave\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb||0px|11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li><strong><span>Webinar Informativo:<\/span><\/strong><span> 6 de Julio de 2026, 15:00\u201317:00 CEST &#8211; <strong><a href=\"https:\/\/erdera.org\/event\/erdera-clinical-trial-call-2026-information-webinar\/\">Link de registro<\/a><\/strong><\/span><\/li>\n<li><strong><span>Stage 0 \u2013 Expression of Interest (EOI):<\/span><\/strong><span> 1\u00a0 de Julio a 10 de Septriembre de 2026<\/span><\/li>\n<li><strong><span>Stage 1 \u2013 Short Proposal Stage:<\/span><\/strong><span> 15 de Septiembre a 29 de Octubre de 2026<\/span><\/li>\n<li><strong><span>Stage 2 \u2013 Support Stage:<\/span><\/strong><span> De Enero a Julio de 2027\u00a0<\/span><\/li>\n<li><strong><span>Stage 3 \u2013 Full Proposal Stage:<\/span><\/strong><span> De Julio a Septiembre de 2027<\/span><\/li>\n<li><strong><span>Funding Decisions:<\/span><\/strong><span> Febrero de 2028<\/span><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb75.9%\u00bb custom_margin=\u00bb-23px|auto||159px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.25.1&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_heading title=\u00bbDocumentaci\u00f3n y enlaces clave\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb title_font=\u00bb|||on|||||\u00bb title_text_color=\u00bb#0C71C3&#8243; min_height=\u00bb0px\u00bb custom_margin=\u00bb1px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover_enabled=\u00bbon|desktop\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00bb4.27.6&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb|||11px||\u00bb hover_enabled=\u00bb0&#8243; global_colors_info=\u00bb{}\u00bb sticky_enabled=\u00bb0&#8243;]<\/p>\n<ul>\n<li data-start=\"6418\" data-end=\"6460\"><a href=\"https:\/\/erdera.org\/call\/ctc2026\/\">Website of the call<\/a><\/li>\n<li data-start=\"6418\" data-end=\"6460\"><a href=\"https:\/\/erdera.org\/wp-content\/uploads\/2026\/06\/ERDERA_Clinical_Trial_Call_Pre-Announcement-1.pdf\">Preanuncio<\/a><\/li>\n<li data-start=\"6418\" data-end=\"6460\"><a href=\"https:\/\/erdera.org\/wp-content\/uploads\/2026\/06\/ERDERA-Clinical-Trial-Budget-example.pdf\">Ejemplo de presupuesto<\/a><\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#195e7f\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb1_4,1_4,1_4,1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_image src=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2023\/04\/Logoblancofondoazul.jpg\u00bb title_text=\u00bbLogoblancofondoazul\u00bb force_fullwidth=\u00bbon\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb transform_scale_tablet=\u00bb202%|202%\u00bb transform_scale_phone=\u00bb202%|202%\u00bb transform_scale_last_edited=\u00bbon|tablet\u00bb transform_translate_tablet=\u00bb75px|25px\u00bb transform_translate_phone=\u00bb85px|-15px\u00bb transform_translate_last_edited=\u00bbon|phone\u00bb transform_translate_linked_tablet=\u00bboff\u00bb transform_rotate_tablet=\u00bb\u00bb transform_rotate_phone=\u00bb\u00bb transform_rotate_last_edited=\u00bbon|tablet\u00bb transform_skew_tablet=\u00bb\u00bb transform_skew_phone=\u00bb\u00bb transform_skew_last_edited=\u00bbon|tablet\u00bb transform_origin_tablet=\u00bb\u00bb transform_origin_phone=\u00bb\u00bb transform_origin_last_edited=\u00bbon|tablet\u00bb transform_styles_last_edited=\u00bbon|phone\u00bb min_height_tablet=\u00bb\u00bb min_height_phone=\u00bb\u00bb min_height_last_edited=\u00bbon|desktop\u00bb custom_margin_tablet=\u00bb||0px|-5px|false|false\u00bb custom_margin_phone=\u00bb||30px|-17px|false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb custom_padding=\u00bb|200px|||false|false\u00bb custom_padding_tablet=\u00bb0px|200px|||false|false\u00bb custom_padding_phone=\u00bb|200px|||false|false\u00bb custom_padding_last_edited=\u00bbon|desktop\u00bb transform_styles_tablet=\u00bb\u00bb transform_styles_phone=\u00bb\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_image][et_pb_text _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb14px|||-11%|false|false\u00bb global_colors_info=\u00bb{}\u00bb]<\/p>\n<p class=\"x_MsoNormal\" style=\"text-align: left;\"><span style=\"color: #ffffff;\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px; float: left;\" \/>Avenida Severo Ochoa, 35, 29590, M\u00e1laga<\/span><\/p>\n<p style=\"color: #ffffff;\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/phone.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px;\" \/>952 36 76 00<\/p>\n<p><a href=\"mailto:info@ibima.eu\" data-linkindex=\"0\" id=\"LPlnk315329\"><img decoding=\"async\" src=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/email.png\" width=\"20\" style=\"position: relative; top: 3px; left: -5px;\" \/>info@ibima.eu<\/a><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][dsm_menu title=\u00bbAPARTADOS PRINCIPALES\u00bb menu_id=\u00bb1332&#8243; menu_link_text_color=\u00bb#FFFFFF\u00bb active_link_color=\u00bb#FFFFFF\u00bb menu_link_text_active_color=\u00bb#FFFFFF\u00bb menu_link_text_visited_color=\u00bb#FFFFFF\u00bb list_style_type=\u00bbnone\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_align=\u00bbleft\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb20px\u00bb custom_margin_tablet=\u00bb200px||||false|false\u00bb custom_margin_phone=\u00bb0px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_menu][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][dsm_menu title=\u00bbTEXTOS LEGALES\u00bb menu_id=\u00bb1333&#8243; menu_link_text_color=\u00bb#FFFFFF\u00bb active_link_color=\u00bb#FFFFFF\u00bb menu_link_text_active_color=\u00bb#FFFFFF\u00bb menu_link_text_visited_color=\u00bb#FFFFFF\u00bb list_style_type=\u00bbnone\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_align=\u00bbleft\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb20px\u00bb custom_margin_tablet=\u00bb-155px||||false|false\u00bb custom_margin_phone=\u00bb0px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_menu][\/et_pb_column][et_pb_column type=\u00bb1_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_social_media_follow _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin_tablet=\u00bb5px||||false|false\u00bb custom_margin_phone=\u00bb5px||||false|false\u00bb custom_margin_last_edited=\u00bbon|tablet\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_social_media_follow_network social_network=\u00bbtwitter\u00bb url=\u00bbhttps:\/\/x.com\/_ibima?lang=es%20&#8243; _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#000000&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]twitter[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbfacebook\u00bb url=\u00bbhttps:\/\/www.facebook.com\/Ibima.eu\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#3b5998&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]facebook[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbinstagram\u00bb url=\u00bbhttps:\/\/www.instagram.com\/ibima_mlg\/\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#ea2c59&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]instagram[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bblinkedin\u00bb url=\u00bbhttps:\/\/es.linkedin.com\/company\/ibima\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#007bb6&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]linkedin[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=\u00bbyoutube\u00bb url=\u00bbhttps:\/\/www.youtube.com\/channel\/UCY3UUZTi9X0ur-1Gd6MKonw\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#a82400&#8243; global_colors_info=\u00bb{}\u00bb follow_button=\u00bboff\u00bb url_new_window=\u00bbon\u00bb]youtube[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][dsm_icon_list _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbBuz\u00f3n de sugerencias\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/ibima.eu\/es\/comunicacion-con-el-instituto\/\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.24.2&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][dsm_icon_list_child text=\u00bbBuz\u00f3n de denuncias\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/ibima.eu\/es\/canal-de-denuncias\/\u00bb url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb custom_margin=\u00bb20px||||false|false\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbSuscr\u00edbete al Canal de Divulgaci\u00f3n\u00bb font_icon=\u00bb&#x3d;||divi||400&#8243; icon_color=\u00bb#FFFFFF\u00bb url=\u00bbhttps:\/\/forms.gle\/5mczd4KKMqkBPdBy7&#8243; url_new_window=\u00bbon\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#FFFFFF\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list_child][\/dsm_icon_list][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Alianza Europea para la Investigaci\u00f3n en Enfermedades Raras (ERDERA) ha lanzado el preanuncio de la ERDERA Clinical Trial Call 2026, una convocatoria destinada a financiar ensayos cl\u00ednicos multinacionales en enfermedades raras. La iniciativa cuenta con un presupuesto de hasta 30 millones de euros y forma parte de la asociaci\u00f3n europea ERDERA, cofinanciada por la [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-61150","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Erdera-Clinical Trial Call 2026.eu - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Erdera-Clinical Trial Call 2026.eu - Ibima\" \/>\n<meta property=\"og:description\" content=\"La Alianza Europea para la Investigaci\u00f3n en Enfermedades Raras (ERDERA) ha lanzado el preanuncio de la ERDERA Clinical Trial Call 2026, una convocatoria destinada a financiar ensayos cl\u00ednicos multinacionales en enfermedades raras. La iniciativa cuenta con un presupuesto de hasta 30 millones de euros y forma parte de la asociaci\u00f3n europea ERDERA, cofinanciada por la [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T08:21:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/\",\"name\":\"Erdera-Clinical Trial Call 2026.eu - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\",\"datePublished\":\"2026-06-08T08:21:41+00:00\",\"dateModified\":\"2026-06-08T08:21:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\",\"contentUrl\":\"https:\\\/\\\/ibima.eu\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/contact.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/erdera-clinical-trial-call-2026-eu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Erdera-Clinical Trial Call 2026.eu\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Erdera-Clinical Trial Call 2026.eu - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/","og_locale":"es_ES","og_type":"article","og_title":"Erdera-Clinical Trial Call 2026.eu - Ibima","og_description":"La Alianza Europea para la Investigaci\u00f3n en Enfermedades Raras (ERDERA) ha lanzado el preanuncio de la ERDERA Clinical Trial Call 2026, una convocatoria destinada a financiar ensayos cl\u00ednicos multinacionales en enfermedades raras. La iniciativa cuenta con un presupuesto de hasta 30 millones de euros y forma parte de la asociaci\u00f3n europea ERDERA, cofinanciada por la [&hellip;]","og_url":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/","og_site_name":"Ibima","article_modified_time":"2026-06-08T08:21:44+00:00","og_image":[{"url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/","url":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/","name":"Erdera-Clinical Trial Call 2026.eu - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/#primaryimage"},"image":{"@id":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/#primaryimage"},"thumbnailUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","datePublished":"2026-06-08T08:21:41+00:00","dateModified":"2026-06-08T08:21:44+00:00","breadcrumb":{"@id":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/#primaryimage","url":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png","contentUrl":"https:\/\/ibima.eu\/wp-content\/uploads\/2024\/03\/contact.png"},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/es\/erdera-clinical-trial-call-2026-eu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Erdera-Clinical Trial Call 2026.eu"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages\/61150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=61150"}],"version-history":[{"count":4,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages\/61150\/revisions"}],"predecessor-version":[{"id":61163,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/pages\/61150\/revisions\/61163"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=61150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}